Research announcement · French Clinical Research Infrastructure Network · 2025-03-27
A two-year trial reported a difference in a measure that combined relapses and changes visible on MRI scans.
A French research network reported results from a trial in people who had experienced a first neurological episode typical of multiple sclerosis. Participants were assigned to vitamin D3 or placebo and followed for up to two years.
Among 303 participants in the main analysis, disease activity occurred in about 60% of the vitamin D group and 74% of the placebo group. The outcome combined a clinical relapse with new or active lesions on MRI, counting either event.
The researchers measured how long it took for the first sign of disease activity, whether a relapse or a change on an MRI scan. The reported midpoint was 432 days in the vitamin D group and 224 days in the placebo group.
